RadTran LLC specializes in nuclear technologies for the advancement of medicine and energy production, developing medical isotopes for diagnostic and therapeutic applications. RadTran is working to develop and commercialize its technology to meet a pressing need in the development of radioimmunotherapy treatments for cancer. The firm has developed a new approach for the generation of Ra224 and Ac225 isotopes. These isotopes have been identified as the most desirable for TAT applications for both direct use and as prerequisites for two other leading medically-attractive isotopes, Pb212 and Bi213. The patent protected technology enables the efficient extraction of target isotopes from naturally occurring stockpiles of Thorium 232 (Th232), a natural waste byproduct of mining, at a dramatically lower cost.
